Skip to main content
SpringerLink
Log in

The Parkinson's disease market

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Shifting composition for the Parkinson's disease market.

References

  1. Datamonitor. Epidemiology: Parkinson's Disease — the aging population will cause the prevalence of Parkinson's disease to continue to grow. HC00039–001 (2011).

  2. Olanow, C. W., Watts, R. L. & Koller W. C. (2001). An algorithm (decision tree) for the management of Parkinson's disease. Neurology, 56 (Suppl. 5), 1–88 (2011).

    Article  Google Scholar 

  3. Olanow, C. W. et al. A double-blind delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268–1278 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Trung Huynh is at Datamonitor, 119 Farringdon Road, London EC1R 3ER, UK. thuynh@datamonitor.com,

    Trung Huynh

Authors
  1. Trung Huynh
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huynh, T. The Parkinson's disease market. Nat Rev Drug Discov 10, 571–572 (2011). https://doi.org/10.1038/nrd3515

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3515

  • Springer Nature Limited

This article is cited by

Search

Navigation